Blog

How to deal with toxicology when developing novel therapeutic modalities.

How skin irritation and corrosion testing based on reconstructed human epidermis models has evolved.

The key safety elements to consider when developing oligonucleotide therapeutics.

Avoid IND and NDA delays by spotting 5 common DART study pitfalls—CMC drift, timing, weak weight-of-evidence, non-relevant species, and poor clinical translation.

Peptide drug conjugates (PDCs) are rapidly emerging as a versatile alternative to traditional antibody-based therapies. Due to their smaller molecular weight, these molecules offer high specificity and improved tissue penetration, though these advantages come with...

Antibody-Drug Conjugates (ADCs) are among the most complex tools in medicine, pairing the precision of antibodies with the power of small-molecule payloads. Creating effective ADCs, however, requires specialized development support. That’s why it’s so important to...

The emergence of Targeted Protein Degradation (TPD) has been an important shift in drug discovery, serving as a method to reach previously "undruggable" proteins. Proteolysis-Targeting Chimeras (PROTACs) are one type of TPD, which unlike other inhibitors, function...

Optimize drug development with mRNA analytical services. WuXi AppTec’s fit-for-purpose testing strategies are designed to ensure regulatory success.

Three strategies to employ when developing next-generation peptide therapeutics

Improve data quality with better in vivo model welfare. See how stress, environment, and GLP practices impact IND-ready toxicology and PK.

Learn four best practices for developing oligonucleotide therapies targeting CNS disorders, including delivery verification, dual-port administration, tissue sampling, and animal model selection.

The mechanisms of ocular toxicity in ADCs and how to manage them.